KRAS and pancreatic neoplasm: Erlotinib is approved as a combination therapy with gemcitabine for certain local pancreatic tumors and has been shown to expand life expectancy (6.24 months) compared with single-agent gemcitabine (5.91 months), although its use is limited by the high frequency of KRAS2 mutations in pancreatic cancers [142,144].